Supplement · Nucleotide Metabolism
Nucleotide Metabolism: Build It, Recycle It, or Pay in Uric Acid
Nucleotides are too expensive to throw away, so the cell mostly recycles them — and the places where that economy breaks (gout, Lesch-Nyhan) and the drugs that exploit it (allopurinol, methotrexate, the leukemia and transplant drugs) are where this chapter earns its keep.
A nucleotide is one of the most expensive small molecules a cell makes, so the cell almost never throws one away. Nucleotides are the letters of DNA and RNA, the carriers of energy (ATP, GTP), the cores of signaling molecules (cyclic AMP), and the backbones of key cofactors (NAD⁺, FAD, coenzyme A). Building their ring systems from scratch costs a small fortune in ATP. The result is a metabolism organized around thrift — and the places where that thrift fails, or where a drug imitates a building block, are where this chapter pays off in the clinic.
Two ways to make a purine
There are two routes to a purine nucleotide, and the difference is mostly about cost.
De novo synthesis builds the purine ring atom by atom directly onto an activated ribose called PRPP. It runs about ten enzymatic steps and spends roughly six ATP to produce the first finished purine nucleotide, IMP, from which both AMP and GMP branch. The committed, regulated step is glutamine-PRPP amidotransferase — the cell’s decision to spend.
Salvage does the opposite of expensive. It takes a free base that already exists — hypoxanthine, guanine, adenine — and reattaches it to PRPP in a single step. HGPRT salvages hypoxanthine and guanine; APRT salvages adenine. Recycling is so much cheaper that cells recover something like ninety percent of their free purines rather than rebuilding them. Salvage is not a backup plan; it is the default.
Knock out HGPRT and salvage breaks. The cell can no longer recycle hypoxanthine or guanine, so it is forced down the wasteful de novo route to keep its purine pools full. Meanwhile the bases it can't salvage pile up and are oxidized to uric acid — hence the hyperuricemia (gout, kidney stones) and the severe neurological disease. One missing enzyme, and the thrifty default becomes both wasteful and toxic.
Most resting tissue salvages — it is cheaper to glue a used base back onto PRPP than to build a ten-carbon-and-nitrogen ring from glutamine, glycine, and CO₂. De novo is the route a rapidly dividing cell pays for when there simply aren't enough scrap bases to go around. The lesson sits in the contrast: salvage is the thrifty default, and Lesch-Nyhan shows what it costs to lose it — you pay twice, once in ATP and once in uric acid.
The cost difference is not academic. When the salvage enzyme HGPRT is missing — an X-linked defect called Lesch-Nyhan syndrome — two bad things happen at once. Free bases that should have been reclaimed are instead dumped into the catabolic pathway and turned into uric acid, and the PRPP that salvage would have consumed piles up and pushes de novo synthesis even higher, making still more purines to degrade. The consequence is severe hyperuricemia alongside profound neurological disease. Losing the recycling program is both wasteful and toxic.
The human endgame: uric acid
When a purine is finally retired, it is taken apart down a short tail: AMP and adenosine funnel through inosine to hypoxanthine, and then the enzyme xanthine oxidase oxidizes hypoxanthine to xanthine and xanthine to uric acid. For most mammals that is not the end — they carry an enzyme called uricase that converts uric acid into highly soluble allantoin. Humans and the other great apes lost a working uricase during evolution. So for us, uric acid is the end product, and it is only sparingly soluble.
That single missing enzyme is why we get gout. Once serum urate climbs past roughly 6.8 mg/dL, it begins to crystallize as monosodium urate, and those needle-sharp crystals in a joint are the flare. The fix is to make less of it: allopurinol, a hypoxanthine look-alike, inhibits xanthine oxidase, so urate production falls and the crystals can dissolve. It is one of the rational-design drugs Gertrude Elion and George Hitchings built by reasoning about the enzyme rather than screening blindly.
Uric acid is where purine catabolism dead-ends in us — we lost uricase, the enzyme other mammals use to break it down further, so the poorly soluble acid is the last stop. Gout is simply that acid crossing its solubility line and crystallizing in a joint. Allopurinol, one of Elion and Hitchings's rationally designed purine analogs, is the elegant fix: it is itself oxidized by xanthine oxidase into oxypurinol, which then jams the enzyme shut — fewer urate molecules made, the serum level falls back under the line, and the crystals dissolve.
Pyrimidines: the ring comes first
Pyrimidine synthesis is worth one contrast. Where purines are assembled directly on the ribose-phosphate scaffold, pyrimidines build the ring first — from carbamoyl phosphate and aspartate — and only attach ribose-phosphate afterward. The carbamoyl phosphate here is made by CPS-II, a cytosolic enzyme that draws its nitrogen from glutamine, and it is deliberately a different enzyme from the mitochondrial CPS-I of the urea cycle. Keeping the two apart lets the cell dispose of nitrogen and build nucleotides without the two jobs interfering.
One more enzyme deserves a name. DNA needs deoxyribonucleotides, and almost all of them are made by reducing the corresponding ribonucleotides through a single gateway, ribonucleotide reductase. Because every dNTP for DNA passes through that one enzyme, its activity is tied tightly to cell division — which makes it, like the rest of this pathway, a target.
Where the chemistry meets the clinic
Nucleotide metabolism is unusually rich in drugs, and they all run on Fischer’s old principle: a molecule’s shape decides what an enzyme will accept. Make a counterfeit that fits the lock well enough to turn it, or to jam it, and you have a medicine.
The dividing cell is the most exposed, because it needs nucleotides fastest. Methotrexate mimics folate and blocks dihydrofolate reductase; 5-fluorouracil mimics uracil and traps thymidylate synthase; both starve a cell of the building blocks it needs to copy its DNA. 6-mercaptopurine, a fake purine, is swallowed by leukemia cells that then choke on it. These are the antimetabolites, and the thread runs straight from Emil Fischer naming the purine ring, to Hitchings and Elion turning that ring into leukemia therapy, transplant drugs, the gout drug above, and the antiviral acyclovir. Understand how the cell builds and recycles its nucleotides, and you understand why these drugs work — and why they hit the fastest-dividing cells hardest of all.
How we measure it
Salvage (phosphoribosyltransfer)
Recycling a free base by attaching it to PRPP in a single step — HGPRT for hypoxanthine and guanine, APRT for adenine. The cheap default, recovering ~90% of free purines.
Antimetabolite drug design
Building a molecule that mimics a real metabolite closely enough to fool an enzyme, then jams it. Allopurinol (xanthine oxidase), methotrexate (DHFR), 5-FU (thymidylate synthase), 6-MP (purine synthesis).
Enzyme inhibition
Blocking a single committed step to choke an entire pathway. The faster a cell divides — a leukemia cell, a microbe — the harder the block bites, which is the therapeutic window.